Treating Patients With NSCLC and High PD-L1 Expression in the First Line

home / case-based-roundtable-series / treating-patients-with-nsclc-and-high-pd-l1-expression-in-the-first-line

This roundtable series evaluates the use of therapies such as monoclonal antibodies in advanced non–small cell lung cancer with high PD-L1 expression, as discussed by participants at virtual live events.

Part 1: Challenges of Choosing Single-Agent Immunotherapy for NSCLC

Part 1: Challenges of Choosing Single-Agent Immunotherapy for NSCLC

Targeted Oncology Staff
May 6th 2022

During a live virtual event, Ravi Salgia, MD, PhD, discussed the use of immune checkpoint inhibitor monotherapy for a patient with non–small cell lung cancer with very high PD-L1 expression with participants.

Part 2: Discussing Brain Metastases and Immunotherapy Duration in NSCLC

Part 2: Discussing Brain Metastases and Immunotherapy Duration in NSCLC

Targeted Oncology Staff
May 27th 2022

During a live virtual event, Ravi Salgia, MD, PhD, discussed treatment considerations for a patient with non–small cell lung cancer with a brain metastasis.

Immunotherapies Offer Alternatives to Chemotherapy for PD-L1–High Lung Cancer

Immunotherapies Offer Alternatives to Chemotherapy for PD-L1–High Lung Cancer

Targeted Oncology Staff
June 27th 2022

During a Targeted Oncology live virtual event, Martin F. Dietrich, MD, PhD, discussed data from 3 trials of immunotherapy agents for patients with non–small cell lung cancer with high PD-L1 expression.

Exploring Subset Analyses in the EMPOWER-Lung 1 Trial for NSCLC

Exploring Subset Analyses in the EMPOWER-Lung 1 Trial for NSCLC

Targeted Oncology Staff
July 29th 2022

During a live virtual event, Martin F. Dietrich, MD, PhD, discussed the results of the EMPOWER-Lung 1 and EMPOWER-Lung 3 trials of cemiplimab for non–small cell lung cancer. This is the second of 2 articles based on this event.